TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Area Under the Concentration-time Curve (AUC) from Time Zero to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Bile leaks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Successful device use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lowest oxygen saturation during bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Development of hypoxemia (SpO2<90%) during bronchoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of complete healing of the target ulcer
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Composite PWID Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prostate Cancer Anxiety
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Composite Complete Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Prednisone Dose Area Under the Curve
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Toxicity of the drug
Endpoint domain: Adverse events/effects
Primary endpoint: Receptor Occupancy on mGlu4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HBV DNA inhibition
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Tacrolimus trough blood concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Time to attain stable therapeutic tacrolimus trough blood concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of out-of-range trough levels during follow-up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acute change in muscle size
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Acute change in muscle function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in microbial load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Risk for multiple beta-cell autoantibodies/type 1 diabetes
Endpoint domain: Mortality/survival
Primary endpoint: Knee functionality
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in social communicative utterances (SCU)
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Appropriate Gestational Weight Gain
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Ability to void after catheter removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percent Predicted FEV1 AUC0-4 Response at the End of Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Percent Predicted FEV1 Trough Response at the End of Week 12
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Enzyme levels in infant stools
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emesis in labor
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Antiretroviral Adherence
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Time spent in the MRI room
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Rate of HBsAg loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peripheral blood specimens collection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean log2 (Fold Change of CD3+ T-Cell Count/µm2) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean log2 (Fold Change of CD3+ Ki67+ Proliferative T Cell Count/µm2) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean log2 (Fold Change of CD4+ FoxP3- Helper T Cell Count/µm2) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean log2 (Fold Change of CD4+ FoxP3+ Regulatory T Cell Count/µm2) Over Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Social adjustment scale
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: The Western Ontario Meniscal Evaluation Tool (WOMET)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of PICD (Paracentesis Induced Circulatory Dysfunction)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change from baseline in HCV RNA viral load (log 10 copies/mL) in GT1 HCV-infected participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in HCV RNA viral load (log 10 copies/mL) in GT3 HCV-infected participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing clinical or laboratory adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Objective measurement of sweat
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of cancer screening
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stage of myometrial placental invasion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Pregnancy and childbirth outcomes
Primary endpoint: Change from Baseline in Ocular Motility Rating Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in EuroQol 5-dimension 5-level (EQ-5D-5L) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Myasthenia Gravis Activities of Daily Living (MG-ADL) score
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Change in Myasthenia Gravis Quality of Life 15-item revised scale (MG-QoL15r) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Composition of fecal microbiota
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum immunoglobulin-A (IgA) level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Bristol stool chart scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Number of Participants With Stabilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline Hepatitis C viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Carpal Tunnel Syndrome Symptom Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCt for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUCinf for Serum Deferiprone and Deferiprone 3-O-glucuronide
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic accuracy of linear measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety after booster administration
Endpoint domain: Adverse events/effects
Primary endpoint: Anteroposterior position changes of upper first molars
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: Anteroposterior position changes of the maxilla
Endpoint domain: Physiological/clinical
Endpoint subdomain: Dental outcomes
Primary endpoint: frequency of relapse
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Thyroid 131I-uptake
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Degree of goiter reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Change in Parent Child Interaction (PCX)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Scores of ocular and eyelid movements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Fold Rise (GMFR) for HI Antibodies Against Flu A/California/7/2009 Strain of Influenza Disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Composite Venous Thromboembolism (VTE) Event
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Major Bleeding or Clinically Relevant Non-major Bleeding
Endpoint domain: Adverse events/effects
Primary endpoint: Long-term protection of induced SARS-CoV2 immunity at 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Long-term protection of induced SARS-CoV2 immunity at 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Kinetics of serum neutralization in blood throughout the study
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in risk for Metabolic Syndrome
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change on Biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Ketosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: blood levels of 25(OH)D
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number of Participants With Immediate Reactions
Endpoint domain: Adverse events/effects
Primary endpoint: Adverse Events Associated With Intranasal Vaccination
Endpoint domain: Adverse events/effects
Primary endpoint: Participants With Serious Adverse Events (SAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Posaconazole trough levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Red Blood Cell Transfusion Independence (RBC-TI) ≥ 8 weeks
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change in World Health Organization (WHO) functional classification
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Treatment-related hematological toxicities (neutropenia) of grade 3-4
Endpoint domain: Adverse events/effects
Primary endpoint: Objective response rate according to RECIST1.1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Return to baseline or predicted pulmonary function
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Ocular safety measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hemagglutination Inhibition (HAI) Titers Specific for Vaccine Homologous A and B Influenza Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: HAI Titers Specific for Antigenically-drifted Influenza Strains
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: serum level of M2BP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Persian version of health assessment questionnaire (PE-HAQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Working Memory Assessed by Domain Deficit Score
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Inflammatory Neuropathy Cause and Treatment (INCAT) scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medical Research Council (MRC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inflammatory Rasch-built Overall Disability Scale (I-RODS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve Over the Dosing Interval (AUC0-tau)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total Clearance (CL) of RO7079901
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Occurrence of adverse events requiring treatment or hospitalization
Endpoint domain: Adverse events/effects
Primary endpoint: Decrease in volume of the pancreatic cyst
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self perceived gender perception
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: IOL stability
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: AUC from dosing to last concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the body weight standardized glucose infusion rate (GIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Amplitude of movement elicited by electrical stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Intervention Uses Resulting in Pain Decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite score of CARS, VABS, and ADI-R
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patients pain value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Concentration of oxy-hemoglobin (HbO2) in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of deoxy-hemoglobin (HHb) in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Concentration of total hemoglobin in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Healthy Eating Index (HEI) Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Portion of patients who maintain vision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Residual ischemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sensitivity of metagenome next generation sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Specificity of metagenome next generation sequencing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Change From Baseline in Fluorescein Corneal Staining Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean reduction in urinary oxalate excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Accuracy parameters of PCCE-2 in detecting colonic polyps
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Magnetoencephalography (MEG) Connectivity Measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Methacholine Responsiveness as Assessed by PC20
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Safe ED discharge
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOLD cerebral response to contextual recall in medial temporal lobe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: BOLD cerebral response to contextual recall in prefrontal cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: CDSS (Calgary Depression Scale for Schizophrenia)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: HAMD (Hamilton Depression Rating Scale)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on Geriatric Depression Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Score on Zarit Caregiver Burden Scale
Endpoint domain: Life impact
Endpoint subdomain: Societal/carer burden
Primary endpoint: Driving Reaction Time to Hazards
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in nitric oxide production
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUCAI score less than 10 at week 6
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pompe disease severity and progression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration Versus Time Curve (AUC) of MMV390048
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Half-life of MMV390048
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline Foot self-care knowledge
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Changes in Health Related Quality of Life (ITR-QOL)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: flare intensity on Day 7
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily symptom variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Quantitative detection of HIV-1 RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Extent of spinal cord injury
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: No PONV Symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of incidental cardiovascular findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Correlation between ingested volume and CSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants With Clinically Significant Abnormal Laboratory Test Results
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinically Significant Abnormal Vital Signs
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With Clinically Significant Abnormal Electrocardiogram (ECG)
Endpoint domain: Adverse events/effects
Primary endpoint: Mean Change From Baseline in Body Mass Index (BMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Biochemical Validated Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Children's Sleep Habits Questionnaire (CSHQ)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Conners' Parent Rating Scale-48 (CPRS-48)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Diagnostic accuracy of wireless capsule endoscopy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cuff Hematoma Measurement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of ADAS-cog total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: NPI scale total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Postoperative BNP concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Interleukin-1 (IL-1) receptor antagonist levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Bone Mineral Density (BMD) at Lumbar Spine and femoral neck
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers of anti-HPV 16 and anti-HPV 18 antibodies
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of subjects who seroconverted or mounted a significant serologic response to each of the 2 antigens 16 and 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Evidence of anal HPV infection, as measured by development of a positive HPV test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Activation of the immune system leading to changes in HIV-1 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Fibromyalgia Impact Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Incidence of a Flare Reaction
Endpoint domain: Adverse events/effects
Primary endpoint: Changes in lean body mass
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Presence of rhythmic risk markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Immature granulocyte count
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Immature granulocyte percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: anti-HPV immune responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Participant confidence
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Need for intervention by a physician to obtain IV access
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Duodenal mucosal transepithelial electrical resistance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duodenal paracellular passage of Fitc Dextran 4 kDa
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glycocholic acid concentration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Successful, complete ablation of the unstained lesions (USLs) within the treatment area (TA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes